By Chelsea Naso ( November 8, 2013, 3:53 PM EST) -- AstraZeneca may be looking to increase its stake in its diabetes joint venture with Bristol-Myers Squibb Co. following on the heels of Bristol's announcement Thursday it would no longer conduct research to discover new drugs for diabetes, hepatitis C and neuroscience, a Citi analyst told Reuters. The analyst estimated Bristol's diabetes business could be worth up to $600 billion, which would bolster AstraZeneca's per share earnings by between 1 and 5 percent....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.